Catch up with what Optometry Times shared this week:

Ocugen Inc announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial

By David Hutton, Managing Editor, Ophthalmology Times

Ocugen Inc announced the FDA has cleared its Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).

Read here...

Study shows increased IPL sessions increased response rate of treatment in moderate-to-severe MGD

By Lynda Charters

A new study reports that increasing the number of intense pulsed light (IPL) sessions is beneficial for patients with moderate-to-severe meibomian gland dysfunction (MGD) to increase the response rate of treatment.¹ The study was conducted by Yang Lu, MD, first author, and colleagues from the Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, and the NHC Key Laboratory of Myopia, Fudan University, both in Shanghai, China.

Read here...

Deciding on Birmingham as site of ADA, Genentech's diabetic eye disease manuscript

By Bryan Wilson, PhD, MBA; Emily Kaiser Maharjan, Assistant Managing Editor; and Jordana Joy, Associate Editor

A recent manuscript published in The American Journal of Accountable Care works to investigate and overview the disproportionate risk that African American Alabamians have in developing diabetes, as well as identify the 4 main pillars of barriers that keeps this population from accessing eye care. Bryan Wilson, PhD, MBA, executive director medical affairs at Genentech, details the decision behind choosing Birmingham, Alabama as the site of the manuscript and what this means for future research.

Watch here...

LENZ Therapeutics announces positive results from Phase 3 CLARITY trials

By Jordana Joy, Associate Editor

Late clinical-stage biopharmaceutical company LENZ Therapeutics has announced positive topline results from its Phase 3 CLARITY study of 2 investigational formulations of aceclidine, LNZ100 (1.75% aceclidine) and LNZ101, designed to treat presbyopia. LNZ100 was selected as the company’s lead candidate, with the primary endpoint met with 71% of participants achieving 3 lines or greater improvement in 3 hours.¹

Read here...

Data and Safety Monitoring Board for Ocugen’s Phase 1/2 ArMaDa clinical approves medium dose of OCU410

By Sydney M Crago, Editor, Modern Retina

The Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial for OCU410 by Ocugen, Inc recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.¹

Read here...